Treatment Outcome in Locally Advanced Rectal Carcinoma and Its Correlation with Hypo-Fractionated Radiotherapy and Concurrent Chemoradiotherapy | [Journal of Pioneering Medical Sciences • 2024]

Author(s):

1. Sadia Sharmin: Department of Clinical Oncology, Bangabandhu Sheikh Mujib Medical University,Dhaka,Bangladesh

2. Nazir Uddin Mollah: Department of Clinical Oncology, Bangabandhu Sheikh Mujib Medical University,Dhaka,Bangladesh

3. Sarwar Alam: Department of Clinical Oncology, Bangabandhu Sheikh Mujib Medical University,Dhaka,Bangladesh

4. Zillur Rahman Bhuiyn: Department of Clinical Oncology, Bangabandhu Sheikh Mujib Medical University,Dhaka,Bangladesh

5. Arif Hasnat: MD (Clinical Oncology), Bangabandhu Sheikh Mujib Medical University,Dhaka,Bangladesh

6. Afsana Sharmin Anika: MD (Clinical Oncology), Bangabandhu Sheikh Mujib Medical University,Dhaka,Bangladesh

Abstract:

Introduction: Rectal cancer is the second most common type within the large intestine, posing significant health risks globally. In Bangladesh, it ranks high among diagnosed cancers. Improved diagnostic methods aid in early detection, which is crucial for effective management. Treatment typically involves a combination of surgery, radiotherapy, and chemotherapy. Preoperative chemoradiotherapy is a standard approach. However, newer methods like preoperative hypofractionated radiotherapy with surgery promise better outcomes, including reduced recurrence rates and enhanced survival, with potential cost and time savings. Aim of the Study: The study aims to evaluate and contrast the efficacy of hypofractionated radiotherapy and concurrent chemoradiotherapy, in patients with locally advanced rectal carcinoma. Methods: The study, conducted at the Department of Clinical Oncology at Bangabandhu Sheikh Mujib Medical University Shahbagh, Dhaka, Bangladesh and the Department of Radiation Oncology at the National Institute of Cancer Research and Hospital (NICR&H) in Mohakhali, Dhaka, Bangladesh, aimed to compare treatments for locally advanced rectal cancer over 1.5 years (From January 2018 to June 2019). A total of 80 patients were divided into two groups; Group A received hypofractionated radiotherapy, while Group B received oral capecitabine alongside external beam radiotherapy. Inclusion criteria involved confirmed adenocarcinoma within specified stages, with ethical clearances obtained. Patients underwent evaluations before treatment and response assessments posttreatment. Treatment modalities were defined, focusing on radiotherapy and chemotherapy. Data were analyzed using SPSS software, employing various statistical tests. Results aimed to address study objectives while minimizing biases. Result: The study involved 80 patients, divided into Groups A and B, each with 40 individuals. Group A mainly comprised individuals aged 41-50 (45%), followed by 31-40 (25%). Group B had the highest proportion aged 31-40 (30%) and 41-50 (32.50%). Both groups showed male predominance (1.3:1). Moderately differentiated tumors were common, with Group A having more poorly differentiated tumors. Stage III was predominant pre-treatment (65% Group A, 70% Group B). Most patients presented with per rectal bleeding (80%) and alteration of bowel habits (56.25%). Response rates to treatment were similar between groups. Tumor downsizing was more frequent in Group B. Sphincter-sparing surgery was feasible in both groups with no significant difference. Conclusion: The study comparing preoperative hypofractionated radiotherapy (RT) to concurrent chemoradiotherapy (CCRT) for locally advanced rectal carcinoma found similar efficacy in tumor response, downsizing, and sphincter preservation. Statistical analysis showed no significant differences. Both approaches showed acceptable short-term outcomes, offering clinicians options based on patient and resource considerations.

Page(s): 115-120

DOI: 10.61091/jpms202413216

Published: Journal: Journal of Pioneering Medical Sciences, Volume: 13, Issue: 2, Year: 2024

Keywords:

Radiotherapy , Chemoradiotherapy , surgical treatment and rectal carcinoma , hypofractionated

References:

[1] Siegel R.,Jemal C.,A. C. .2014 .. Cancer Journal for Clinicians, 64(2) : 104-117.

[2] Torre L. A.,Siegel R. L.,Ward E. M.,Jemal A. .2016 .Global cancer incidence and mortality rates and trends-an update. Biomarkers & Prevention, 25(1) : 16-27.

[3] Bray F.,Ferlay J.,Soerjomataram I.,Siegel R. L.,Torre L. A.,Jemal A. .2018 .GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 68(6) : 394-424.

[4] Fazeli M. S.,Keramati M. R. .2015 .Rectal cancer: a review. Medical Journal of the Islamic Republic of Iran, 29 : 171.

[5] Lemmens V.,Steenbergen L. V.,Janssen-Heijnen M.,Martijn H.,Rutten H.,Coebergh J. W. .2010 .Trends in colorectal cancer in the south of the Netherlands 1975-2007: rectal cancer survival levels with colon cancer survival. Acta oncologica, 49(6) : 784-796.

[6] Glimelius B. .2012 .Multidisciplinary treatment of patients with rectal cancer: Development during the past decades and plans for the future. Upsala Journal of Medical Sciences, 117(2) : 225-236.

[7] Beppu N.,Yanagi H.,Tomita N. .2017 .A review of preoperative chemoradiotherapy for lower rectal cancer. Journal of the Anus, Rectum and Colon, 1(3) : 65-73.

[8] Kim H. S.,Kim N. K. .2020 .Challenges and shifting treatment strategies in the surgical treatment of locally advanced rectal cancer. Annals of Gastroenterological Surgery, 4(4) : 379-385.

[9] Kye B. H.,Cho H. M. .2014 .Overview of radiation therapy for treating rectal cancer. Annals of Coloproctology, 30(4) : 165-174.

[10] Krishnamurthi S. S.,Seo Y.,Kinsella T. J. .2007 .Adjuvant therapy for rectal cancer. Clinics in Colon and Rectal Surgery, 20(03) : 167-181.

[11] Abraha I.,Aristei C.,Palumbo I.,Lupattelli M.,Trastulli S.,Cirocchi R.,Valentini V. .2018 .Preoperative radiotherapy and curative surgery for the management of localised rectal carcinoma. The Cochrane Database of Systematic Reviews, 10(10) : CD002102.

[12] Cancer Observatory Global .2018 .. , : .

[13] Hospital-Based Cancer Registry Report NICRH .2014 .. , : .

[14] Sauer R.,Becker H.,Hohenberger W.,Rödel C.,Wittekind C.,Fietkau R.,Raab R. .2004 .Preoperative versus postoperative chemoradiotherapy for rectal cancer. New England Journal of Medicine, 351(17) : 1731-1740.

[15] Yoney A.,Isikli L. .2014 .Preoperative chemoradiation in locally advanced rectal cancer: a comparison of bolus 5-fluorouracil/leucovorin and capecitabine. Saudi Journal of Gastroenterology, 20(2) : 102-107.

[16] Hamilton W.,Round A.,Sharp D.,Peters T. J. .2005 .Clinical features of colorectal cancer before diagnosis: a population-based case-control study. British Journal of Cancer, 93(4) : 399-405.

[17] Kunheri B.,Gurram B.,Madhavan R.,Makuny D. .2016 .Preoperative long-course chemoradiation for localized rectal cancer: A retrospective comparison of response and outcome between 5- lfuorouracil/leucovorin versus capecitabine. Indian Journal of Cancer, 53(4) : 518-523.

[18] Ryan O,'Sullivan D. P.,Kelly M. E.,Syed A. Z.,Neary P. C.,O'Connell P. R.,O'Riordan J. M. .2019 .Meta-analysis of the effect of extending the interval after long-course chemoradiotherapy before surgery in locally advanced rectal cancer. Journal of British Surgery, 106(10) : 1298-1310.

[19] Yoney A.,Isikli L. .2014 .Preoperative chemoradiation in locally advanced rectal cancer: a comparison of bolus 5-fluorouracil/leucovorin and capecitabine. Saudi Journal of Gastroenterology, 20(2) : 102-107.

Citations

Downloads

Views